Perrigo gains final FDA approval for generic topical steroid cream
Dennis R.J. Geppert/The Holland Sentinel
Perrigo has won USDA final approval to begin shipments of the generic equivalent of Cutivate
The U.S. Food and Drug Administration has granted final approval to Perrigo Company for the Allegan-based drugmaker’s abbreviated new drug application of the generic equivalent of Cutivate Lotion 0.05%, the company announced this morning.
Perrigo said it plans to begin shipments immediately of the topical steroid cream, which boasts annual sales of approximately $19 million, according to Symphony Health Solutions.
“This is another example of our Rx team’s commitment to launching difficult-to-manufacture topicals, lotions and foams,” Perrigo Chairman and CEO Joseph C. Papa said in a news release. “We are excited to market this product and are dedicated to making quality healthcare more affordable for all consumers around the globe.”
Fluticasone propionate lotion, which is marketed under the brand name Cutivate, is used to reduce itching, redness and swelling associated with several skin conditions. It has been proven effective for the treatment of children ages 1 and older.
— Follow this reporter on Twitter @BizHolland